Overview

Comparison of CDB-2914 Versus Placebo in the Prevention of Follicular Rupture Post-luteinizing Hormone (LH) Surge

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Evaluation of the effect of a single dose of CDB-2914, as compared to placebo, administered after the onset of the LH surge on the outcome of the leading ovary follicle: - echographic follicle rupture - inhibition of follicle rupture - luteal phase progesterone levels - anovulatory progesterone levels
Phase:
Phase 2
Details
Lead Sponsor:
HRA Pharma
Treatments:
Ulipristal acetate